Anadys Pharmaceuticals to Present at BioCentury's 12th Anniversary Newsmakers in the Biotech Industry Conference
Anadys Pharmaceuticals to Present at BioCentury's 12th Anniversary Newsmakers in the Biotech Industry Conference


SAN DIEGO, Sept. 2 -- Anadys Pharmaceuticals, Inc.
(Nasdaq: ANDS) announced today that it will be presenting at BioCentury's 12th
Anniversary NewsMakers in the Biotech Industry Conference on Friday, September
9, 2005, at 1:20 p.m. Eastern Time in the Liberty 3 suite at the Sheraton New
York Hotel & Towers, 811 Seventh Avenue, New York City. The presentation will
be simultaneously webcast and can be accessed on the Company's website at
http://www.anadyspharma.com.
Kleanthis G. Xanthopoulos, Ph.D., Anadys' President and Chief Executive
Officer, will present an overview of Anadys and its clinical development and
discovery programs.
Listeners are encouraged to visit the website approximately 5 minutes
prior to Anadys' presentation to download or install any necessary software. A
replay of the presentation will become available approximately one hour after
the live webcast concludes and will be archived and available until September
23, 2005.

About Anadys
Anadys Pharmaceuticals, Inc. is a biopharmaceutical company committed to
advancing patient care by discovering, developing and commercializing novel
small molecule medicines for the treatment of hepatitis C virus (HCV),
hepatitis B virus (HBV) and other serious infections. The Company has core
expertise in Toll-Like Receptor-based small molecule therapeutics and
structure-based drug design coupled with medicinal chemistry. Anadys'
clinical development programs include ANA975 for the treatment of HCV and HBV,
and ANA380 for the treatment of HBV. In addition, Anadys' therapeutic platform
is designed to advance a strong and continual pipeline of drug candidates into
the clinic.

Safe Harbor Statement
Statements in this press release that are not strictly historical in
nature constitute "forward-looking statements." Such forward-looking
statements involve known and unknown risks, uncertainties and other factors,
which may cause Anadys' actual results to be materially different from
historical results or from any results expressed or implied by such forward-
looking statements. In particular, the results of initial clinical trials may
not be predictive of future results, and Anadys cannot provide any assurances
that any of its product candidates will have favorable results in future
clinical trials or receive regulatory approval. In addition, Anadys' results
may be affected by risks related to the implementation of its collaboration
with Novartis, competition from other biotechnology and pharmaceutical
companies, its effectiveness at managing its financial resources, its ability
to successfully develop and market products, the level of efforts that its
collaborative partners devote to development and commercialization of its
product candidates, difficulties or delays in its clinical trials,
difficulties or delays in manufacturing its clinical trials materials, the
scope and validity of patent protection for its products, regulatory
developments involving future products and its ability to obtain additional
funding to support its operations. These and other factors that may cause
actual results to differ are more fully discussed in the "Risk Factors"
section of Anadys' Form 10-Q for the quarter ended June 30, 2005. All forward-
looking statements are qualified in their entirety by this cautionary
statement. Anadys is providing this information as of this date and does not
undertake any obligation to update any forward-looking statements contained in
this document as a result of new information, future events or otherwise.



SOURCE Anadys Pharmaceuticals, Inc.
Web Site: http://www.anadyspharma.com

Biotech News

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech